all report title image
  • Published In : May 2024
  • Code : CMI1728
  • Pages :205
  • Formats :
      Excel and PDF
  • Industry : Biotechnology
Market Challenge – High Cost of Cell Therapies

High cost of cell therapies is one of the biggest challenges, with financial implications for patients, payers, and providers, and this is expected to hamper the market growth over the forecast period. For instance, in May 2022, chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) received the U.S. FDA approval for the treatment of pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).It costs around US$ 475,000 for a single infusion. This has resulted in limited adoption of such therapies, thus, hampering growth of the market. Moreover, in April 2022, Yescarta, a cell therapy, developed by Kite Pharma, Inc., a pharmaceutical company, was approved by the U.S. FDA for the treatment of certain B-cell lymphomas. The listed price for axicabtagene ciloleucel (Yescarta) in the U.S. is US$ 373,000.

Market Opportunity– Increasing Investments by Key Market Players

Increasing adoption of inorganic growth strategies such as investments is expected to drive growth of the global cell therapy manufacturing market. For instance, on February 6, 2024, AstraZeneca, a global pharmaceutical company, announced that it  had invested US$ 300 million in a facility in Rockville, Maryland, U.S. for discovery and development of cell therapies. The aim of the investment is to launch its life-saving cell therapy platforms in the U.S. for critical cancer trials and future commercial supply.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.